Related Experiment Video
Updated: Feb 25, 2026
Microscale Vortex-assisted Electroporator for Sequential Molecular Delivery
Published on: August 7, 2014
Microfluidic Transduction Harnesses Mass Transport Principles to Enhance Gene Transfer Efficiency
Reginald Tran1, David R Myers1, Gabriela Denning2
1Division of Pediatric Hematology/Oncology, Department of Pediatrics, Aflac Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, GA 30322, USA; Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA 30332, USA.
A new microfluidic method enhances ex vivo gene therapy, making lentiviral vector (LV) gene transfer faster and more efficient. This scalable approach uses significantly less vector, improving accessibility for treating blood disorders.
Area of Science:
- Biotechnology
- Gene Therapy
- Cellular Engineering
Background:
- Ex vivo gene therapy using lentiviral vectors (LVs) shows promise for hematologic disorders but faces manufacturing and transduction limitations.
- Current methods are costly, difficult to scale, and require excessive vector, hindering widespread clinical application.
- Inefficient transduction protocols limit the efficiency of gene transfer in target cells.
Purpose of the Study:
- To develop a novel microfluidic platform for enhanced ex vivo lentiviral vector transduction.
- To overcome diffusion limitations and improve gene transfer kinetics and efficiency.
- To create a scalable, user-friendly, and cost-effective gene therapy manufacturing process.
Main Methods:
- A microfluidic, mass transport-based approach was designed to enhance LV gene transfer.
- The platform was tested using hematopoietic cell lines, primary human T cells, and murine/human hematopoietic stem and progenitor cells (HSPCs).
- In vivo validation involved gene therapy in hemophilia A mice using microfluidic-transduced HSPCs.
Main Results:
- Microfluidic transduction was up to 5-fold faster than traditional methods.
- The novel platform required up to 20 times less LV for efficient gene transfer.
- In vivo studies showed restored clotting levels in hemophilia A mice treated with microfluidic-transduced cells.
Conclusions:
- The microfluidic platform significantly enhances lentiviral vector gene transfer efficiency and kinetics.
- This technology offers a scalable, cost-effective solution for ex vivo gene therapy production.
- The approach holds potential for broader clinical utilization in treating genetic blood disorders.
